Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-11-04
2011-12-13
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S403000
Reexamination Certificate
active
08076342
ABSTRACT:
4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen malonate salt and pharmaceutical comprising and uses of the same, including for the treatment of schizophrenia and other psychotic disorders are described.
REFERENCES:
patent: 4031216 (1977-06-01), Cyrus et al.
patent: 4443448 (1984-04-01), Bogeso
patent: 4616086 (1986-10-01), Witte et al.
patent: 5026853 (1991-06-01), Van Daele et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5561057 (1996-10-01), Trani et al.
patent: 5807855 (1998-09-01), Bogeso et al.
patent: 5807897 (1998-09-01), Warawa et al.
patent: 6103719 (2000-08-01), Esser et al.
patent: 6153611 (2000-11-01), Mattson et al.
patent: 6410794 (2002-06-01), Zinnen et al.
patent: 6444854 (2002-09-01), Dapremont et al.
patent: 6455736 (2002-09-01), Zinnen et al.
patent: 6506940 (2003-01-01), Jadav et al.
patent: 6635645 (2003-10-01), Lochead et al.
patent: 2010/0105699 (2010-04-01), Bang-Andersen et al.
patent: 0035363 (1981-09-01), None
patent: 0638073 (2000-06-01), None
patent: 0638073 (2000-06-01), None
patent: 06184132 (1994-05-01), None
patent: 2000/351773 (2000-12-01), None
patent: 93/08799 (1993-05-01), None
patent: 93/22293 (1993-11-01), None
patent: 95/15299 (1995-06-01), None
patent: 99/42107 (1999-08-01), None
patent: 99/61426 (1999-12-01), None
patent: 99/62893 (1999-12-01), None
patent: 00/12073 (2000-03-01), None
patent: 00/34284 (2000-06-01), None
patent: 00/75172 (2000-12-01), None
patent: 00/76961 (2000-12-01), None
patent: 00/78708 (2000-12-01), None
patent: 2005/016900 (2005-02-01), None
patent: 2005/016901 (2005-02-01), None
patent: 2006/086984 (2006-08-01), None
patent: 2006/086985 (2006-08-01), None
patent: 2006/086986 (2006-08-01), None
Balsara, J. J., et al. “Effect of Drugs Influencing Central Serotonergic Mechanisms on Haloperidol-Induced Catalepsy”, Psychopharmacol. 62:67-69 (1979).
Bøgesø, K. P. “Neuroleptic Activity and Dopamine-Uptake Inhibition in 1-Piperazino-3-phenylindans”, J. Med. Chem. 26(7):935-47 (1983).
Bøgesø, K. P., et al. “3-Phenyl-1-indanamines—Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake”, J. Med. Chem. 28:1817-28 (1985).
Bøgesø, K. P., et al. “Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindanes with Potential Atypical Antipsychotic Activity”, J. Med. Chem. 43:4981-92 (1995).
Bøgesø, K. P. Drug Hunting: The medicinal chemistry of 1-piperazino-3-phenylindans and related compounds. Vibørg, Denmark: Nørhaven (1998).
Carlsson, A. “Antipsychotic Drugs, Neurotransmitters, and Schizophrenia”, Am. J. Psych. 135(2):164-73 (1978).
Carlsson, L., et al. “QTU-Prolongation and Torsades de Pointes Induced by Putative Class III Antiarrhythmic Agents in the Rabbit: Etiology and interventions”, J. Cardiovasc. Pharmacol. 16:276-85 (1990).
Chauret, N., et al. “The Use of 3-[2-(N,N-Diethyl-N-Methylammonium)Ethyl]-7-Methoxy-4-Methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes”, Drug Metab. Dispos. 29(9):1196-200 (2001).
Clark, W. M., et al. “A Catalytic Enantioselective Synthesis of the Endothelin Receptor Antagonists SB-209670 and SB-217242. A base-catalyzed stereospecific formal 1,3-hydrogen transfer of a chiral 3-arylindenol”, J. Am. Chem. Soc. 120:4550-51 (1998).
Clark, W. M., et al. “A Highly Enantioselective Conjugate Reduction of 3-Arylinden-1-ones Using Bakers' Yeast for the Preparation of (S)-3-Arylindan-1-ones”, Org. Lett. 1(11):1839-42 (1999).
Davies, H. M. L., et al. “Asymmetric Synthesis of (+)-Indatraline Using Rhodium-Catalyzed C-H Activation”, Tetrahedron Lett.
Desiraju, G. R. “Cryptic Crystallography,” Nature Mater. 1:77-79 (Oct. 2002).
Eder, D. N. “CEE-03-310 CeNeS Pharmaceuticals,” Curr. Op. Invest. Drugs. 3(2)284-88 (2002).
Froimowitz M., et al. “Slow-Onset, Long-Duration 3-(3′,4′-Dichlorophenyl)-1-Indanamine Monoamine Reuptake Blockers as Potential Medications to Treat Cocaine Abuse”, J. Med. Chem. 43(26):4981-92 (Dec. 2000).
Gonzalez-Gomez, J.C., et al. “New Arylpiperazine Derivatives with High Affinity for alpha 1A, D2 and 5-HT2A Receptors”, Bioorg. Med. Chem. Lett. 13:175-78 (2003).
Haleblian, J., et al. “Pharmaceutical Applications of Polymorphism”, J. Pharmaceut. Sci. 58(8):911-29 (1969).
Hyttel, J., et al. “Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin”, J. Neurochem. 44:1615-22 (1985).
Millan, M. J., et al. “S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors: I. Receptorial. Neurochemical, and Electrophysiological Profile”, J. Pharmacol. Exp. Ther. 292(1):38-53 (2000).
Newman, A. H. “Novel pharmacotherapies for cocaine abuse 1997-2000”, Exp. Opin. Ther. Patents. 10(7):1095-122. (2000).
Price, S. L. “The Computational Prediction of Pharmaceutical Crystal Structures and Polymorphism,” Adv. Drug Delivery Rev. 56:301-19 (2004).
Robichaud, A. J., et al. “Recent Advances in Selective Serotonin Receptor Modulation”, Ch. 2 in Ann. Rep. Med. Chem. 35: 11-20, Raleigh, NC: Academic Press (Elsevier) (2000).
Seeman, P. “Dopamine Receptors and Psychosis”, Sci. Am. 2:28-37 (1995).
Sommer, M. B., et al. “Application of (2-Cyanoaryl)arylacetonitriles in Cyclization and Annulation Reactions. Preparation of 3-Arylindans, 4-Aryl-3,4-dihydronaphthalenes, 4-Arylisoquinolines, 1-Aminonaphthalenes, and Heterocyclic Analogues”, J. Org. Chem. 55:4822-4827 (1990).
University of Cambridge “Major advances made in predicting crystal structures”, Physics-Condensed Matter. (Nov. 26, 2007); available on line at www.physorg.com/pring1153104.
Pedersen, V. and K. Brøgesø “Drug Hunting,” in Interviews by David Healy, The Psychopharmacologists II, pp. 561-579, London: Arnold (1999).
Willner, P. “Dopamine and Depression: A review of recent evidence. I. Empirical studies”, Brain Res. Rev. 6 (3):211-224 (1983).
Willner, P. “Dopamine and Depression: A review of recent evidence. II. Theoretical approaches”, Brain Res. Rev. 6 (3):225-236 (1983).
Willner, P. “Dopamine and Depression: A review of recent evidence. III. The effects of antidepressant treatments,” Brain Res. Rev. 6(3):237-246 (1983).
Yun, J., et al. “Efficient Kinetic Resolution in the Asymmetric Hydrosilylation of Imines of 3-Substituted Indanones and 4-Substituted Tetralones”, J. Org. Chem. 65(3):767-774 (2000).
Zhang, A., et al. “Recent Advances Towards the Discovery of Dopamine Receptor Ligands,” Expert Op. Ther. Patents. 16(5):587-630 (2006).
Adler, L., et al., “Schizophrenia, sensory gating, and nicotinic receptors”, Schizophrenia Bulletin, 1998; 24(2):189-202.
Allan, G., et al., “One-pot deracemisation of an enol acetate derived from a prochiral cyclohexanone”, Tetrahedron Letters, 2001; 42:5959-5962.
Bastin, R.J., et al., “Salt selection and optimisation procedures for pharmaceutical new chemical entities,” Organic Process Research & Development, 2000; 4:427-435.
Birrell, J., et al., “Medial frontal cortex mediates preceptual attentional set shifting in the rat”, Journal of Neuroscience, 2000; 20(11):4320-4324.
Bogeso, K.P., et al., “Stereospecific and selective 5-HT2 antagonism is a series of 5-substituted trans-1-piperazino-3-phenylindans,” J. Med. Chem., 1993, 36:2761-2770.
Dinh, P., et al., “Catalytic racemisation of alcohols: applications to enzymatic resolution reactions”, Tetrahedron Letters, 1996; 37(42):7623-7626.
Farde, L., et al., “Positr
Bang-Andersen Benny
Dahl Allan Carsten
Howells Mark
Lopez de Diego Heidi
Lyngso Lars Ole
Bernhardt Emily
Buck Margaret M.
Kalinchak Stephen G.
Kohli Vineet
LandOfFree
Malonate salt of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Malonate salt of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Malonate salt of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4255942